Drugs / Aquamin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02647671 | Apr 2016 → Mar 2021 | colorectal cancer | James Varani | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07501078 | Jul 2026 → May 2029 expected | ulcerative colitis | Muhammad N Aslam, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05058638 | Aug 2022 → Dec 2026 expected | extraoral halitosis due to methanethiol oxidase deficiency | University of Michigan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04855799 | Nov 2021 → Mar 2024 | irritable bowel syndrome, ulcerative colitis | James Varani | Completed | No outcome recorded |
| Phase 2 | NCT03869905 | Aug 2019 → Dec 2027 expected | ulcerative colitis | Muhammad N Aslam, MD | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aquamin | “The long-term goal of our ongoing studies is to determine if, and to what extent, a multi-mineral product (Aquamin) could benefit individuals with ulcerative colitis (UC).” PMID 41359652 ↗ Dec 20256“a natural mineral supplement called Aquamin®” NCT07501078 ↗ |
| Modality | Other / unclassified | “Aquamin®, a Multi-mineral Natural Product From Red Marine Algae” NCT03869905 ↗ |
| Route | Oral | “Participants will take capsules containing the assigned study agent (the multi-mineral natural product or calcium or placebo) for 90 days.” NCT02647671 ↗ |